Samsung Bioepis Aims To Compete On Higher-Strength Humira In US

FDA Accepts sBLA For 100mg/ml Citrate-Free Version Of Hadlima Biosimilar

 
• By David Wallace
  
Dial High Black Red
Samsung Bioepis is targeting high-concentration adalimumab • Source: igor kisselev / Alamy Stock Vector
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products